BioSyngen

BioSyngen Focuses on Untapped Areas in Cancer Research, Developing Multiple Immune Cell Products. BioSyngen possesses world-leading innovative T-cell immunotherapy and gathers scientific talents from five regions—Singapore, China, Germany, Australia, and France. Through a diversified, multi-level R&D strategy involving independent research, collaborative development, and licensed technology acquisition, the company is dedicated to addressing unmet challenges in cancer treatment. By leveraging tumor immune cell therapy technology, BioSyngen aims to fundamentally eliminate tumors, benefiting cancer patients in China and globally. BioSyngen has established the world's largest and most comprehensive library of EB virus CARs and TCRs, and is currently conducting clinical trials across multiple centers for various indications such as nasopharyngeal carcinoma, gastric cancer, and lymphoma.